Cargando…
Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683296/ https://www.ncbi.nlm.nih.gov/pubmed/29388634 http://dx.doi.org/10.2147/PHMT.S90688 |